Sublytic complement protects prostate cancer cells from tumour necrosis factor-α-induced cell death

Clinical and Experimental Immunology

Volumn 169, Issue 2, 2012, Pages 100-108

  Liu, L ^a,c   Li, W ^c   Li, Z ^b   Kirschfink, M ^c  

^a Tongji Hospital   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cell death; Complement; DU145; TNF

Indexed keywords

COMPLEMENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BCL 2; PROTEIN BCL XL; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROTECTION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR MICROENVIRONMENT;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASE 8; CELL DEATH; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; ENZYME ACTIVATION; HUMANS; MALE; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863559729     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2012.04596.x     Document Type: Article

References (69)

1. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44.
2. Lorusso G, Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008; 130:1091-103.
3. Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058-66.
4. Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140-4.
5. Rus H, Cudrici C, Niculescu F. The role of the complement system in innate immunity. Immunol Res 2005; 33:103-12.
6. Lucas SD, Karlsson-Parra A, Nilsson B etal. Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 1996; 27:1329-35.
7. Niculescu F, Rus HG, Retegan M, Vlaicu R. Persistent complement activation on tumor cells in breast cancer. Am J Pathol 1992; 140:1039-43.
8. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996; 149:129-42.
9. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 2009; 30:286-92.
10. Gancz D, Fishelson Z. Cancer resistance to complement-dependent cytotoxicity (CDC): problem-oriented research and development. Mol Immunol 2009; 46:2794-800.
11. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 2003; 40:109-23.
12. Jurianz K, Ziegler S, Garcia-Schuler H etal. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999; 36:929-39.
13. Rozanov DV, Savinov AY, Golubkov VS, Tomlinson S, Strongin AY. Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res 2006; 66:6258-63.
14. Ollert MW, Frade R, Fiandino A etal. C3-cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells. J Immunol 1990; 144:3862-7.
15. Pilzer D, Saar M, Koya K, Fishelson Z. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity. Int J Cancer 2010; 126:1428-35.
16. Jurianz K, Ziegler S, Donin N, Reiter Y, Fishelson Z, Kirschfink M. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int J Cancer 2001; 93:848-54.
17. Odening KE, Li W, Rutz R etal. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells. Clin Exp Immunol 2009; 155:239-48.
18. Reiter Y, Ciobotariu A, Fishelson Z. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur J Immunol 1992; 22:1207-13.
19. Reiter Y, Ciobotariu A, Jones J, Morgan BP, Fishelson Z. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J Immunol 1995; 155:2203-10.
20. Carney DF, Lang TJ, Shin ML. Multiple signal messengers generated by terminal complement complexes and their role in terminal complement complex elimination. J Immunol 1990; 145:623-9.
21. Cybulsky AV, Bonventre JV, Quigg RJ, Lieberthal W, Salant DJ. Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury. Kidney Int 1990; 38:803-11.
22. Kraus S, Seger R, Fishelson Z. Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin Exp Immunol 2001; 123:366-74.
23. Niculescu F, Rus H, Shin S, Lang T, Shin ML. Generation of diacylglycerol and ceramide during homologous complement activation. J Immunol 1993; 150:214-24.
24. Shirazi Y, McMorris FA, Shin ML. Arachidonic acid mobilization and phosphoinositide turnover by the terminal complement complex, C5b-9, in rat oligodendrocyte × C6 glioma cell hybrids. J Immunol 1989; 142:4385-91.
25. Soane L, Cho HJ, Niculescu F, Rus H, Shin ML. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol 2001; 167:2305-11.
26. Soane L, Rus H, Niculescu F, Shin ML. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J Immunol 1999; 163:6132-8.
27. Zwaka TP, Torzewski J, Hoeflich A etal. The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop. FASEB J 2003; 17:1346-8.
28. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666-70.
29. Pennica D, Nedwin GE, Hayflick JS etal. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312:724-9.
30. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214:149-60.
31. Vandenabeele P, Declercq W, Van Herreweghe F, Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal 2010; 3:re4.
32. Sethi G, Sung B, Kunnumakkara AB, Aggarwal BB. Targeting TNF for treatment of cancer and autoimmunity. Adv Exp Med Biol 2009; 647:37-51.
33. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000; 50:184-95.
34. Naismith JH, Sprang SR. Modularity in the TNF-receptor family. Trends Biochem Sci 1998; 23:74-9.
35. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995; 81:495-504.
36. Chen G, Goeddel DV. TNF-R1 signalling: a beautiful pathway. Science 2002; 296:1634-5.
37. Holler N, Zaru R, Micheau O etal. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1:489-95.
38. Malik ST. Tumour necrosis factor: roles in cancer pathophysiology. Semin Cancer Biol 1992; 3:29-33.
39. Plantivaux A, Szegezdi E, Samali A, Egan L. Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance? Ann NY Acad Sci 2009; 1171:38-49.
40. Jurianz K, Maslak S, Garcia-Schuler H, Fishelson Z, Kirschfink M. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 1999; 42:209-18.
41. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9:361-71.
42. Tamatani M, Che YH, Matsuzaki H etal. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem 1999; 274:8531-8.
43. Takase O, Minto AW, Puri TS etal. Inhibition of NF-kappaB-dependent Bcl-xL expression by clusterin promotes albumin-induced tubular cell apoptosis. Kidney Int 2008; 73:567-77.
44. Wu S, Boyer CM, Whitaker RS etal. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res 1993; 53:1939-44.
45. van den Berg JM, Weyer S, Weening JJ, Roos D, Kuijpers TW. Divergent effects of tumor necrosis factor alpha on apoptosis of human neutrophils. J Leukoc Biol 2001; 69:467-73.
46. Funk JO, Walczak H, Voigtlander C etal. Cutting edge: resistance to apoptosis and continuous proliferation of dendritic cells deficient for TNF receptor-1. J Immunol 2000; 165:4792-6.
47. Wallach D. Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol 1984; 132:2464-9.
48. Bersani L, Colotta F, Ghezzi P, Mantovani A. Rapid killing of actinomycin d-treated tumor cells - cytotoxicity of cell-free monocyte supernatants. Immunol Lett 1985; 11:351-5.
49. Colotta F, Polentarutti N, Bersani L, Poli G, Mantovani A. Rapid killing of actinomycin D-treated tumor cells by mononuclear phagocytes: characterization of effector cells in mice. J Leukoc Biol 1986; 39:205-21.
50. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, Old LJ. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 1983; 80:5397-401.
51. Schlager SI, Ohanian SH, Borsos T. Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid. J Immunol 1978; 120:463-71.
52. Muller-Eberhard HJ. The membrane attack complex. Springer Semin Immunopathol 1984; 7:93-141.
53. Soldani C, Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002; 7:321-8.
54. Smulson ME, Pang D, Jung M etal. Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: possible role in apoptosis. Cancer Res 1998; 58:3495-8.
55. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116:205-19.
56. Zhang XD, Zhang XY, Gray CP, Nguyen T, Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 2001; 61:7339-48.
57. Srinivasan A, Li F, Wong A etal. Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells. J Biol Chem 1998; 273:4523-9.
58. Sutherland KA, Rogers HL, Tosh D, Rogers MJ. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 2009; 11:R58.
59. Hila S, Soane L, Koski CL. Sublytic C5b-9-stimulated Schwann cell survival through PI 3-kinase-mediated phosphorylation of BAD. Glia 2001; 36:58-67.
60. Cudrici C, Niculescu F, Jensen T etal. C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP. J Immunol 2006; 176:3173-80.
61. Khoshnan A, Tindell C, Laux I, Bae D, Bennett B, Nel AE. The NF-kappa B cascade is important in Bcl-xL expression and for the anti-apoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 2000; 165:1743-54.
62. Zhang H, Yan D, Shi X etal. Transmembrane TNF-alpha mediates 'forward' and 'reverse' signalling, inducing cell death or survival via the NF-kappaB pathway in Raji Burkitt lymphoma cells. J Leukoc Biol 2008; 84:789-97.
63. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989; 264:1-14.
64. Kraus S, Fishelson Z. Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C. Eur J Immunol 2000; 30:1272-80.
65. Birkenkamp KU, Geugien M, Schepers H, Westra J, Lemmink HH, Vellenga E. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004; 18:103-12.
66. Burow ME, Weldon CB, Melnik LI etal. PI3-K/AKT regulation of NF-kappaB signalling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun 2000; 271:342-5.
67. Santiago C, Pagan B, Isidro AA, Appleyard CB. Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitis-associated colon cancer. Cancer Res 2007; 67:10766-73.
68. Markiewski MM, DeAngelis RA, Benencia F etal. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9:1225-35.
69. Fishelson Z, Attali G, Mevorach D. Complement and apoptosis. Mol Immunol 2001; 38:207-19.